Relmada Therapeutics (RLMD) earnings

RELMADA THERAPEUTICS, INC.· Health Care

Results to: Jun 2026
Latest analysed call: Jun 2026 (Q2 FY26)
Balance sheet to: Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

Relmada Therapeutics earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	Unavailable	—	Quarterly, as filed	Quarter to Jun 2026	Not in the filed figures for the quarter to jun 2026. No older figure is substituted.
Operating margin	Unavailable	—	Operating profit / revenue	Quarter to Jun 2026	Not in the filed figures for the quarter to jun 2026. No older figure is substituted.
Net profit	-12.9 $ million	—	Quarterly, as filed	Quarter to Jun 2026	Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.

Source: Inve data from filed results (SEC filings) · to Jun 2026

Price

$3.2 −1.23% · −$0.04

Last close Oct 15, 2026 · US · USD

Performance +65.8% 1Y

1Y: $1.93 on 14 Oct 2025 → $3.2. High $7.86 (6 May 2026), low $1.93 (14 Oct 2025).

Previous close: $3.24
52-week range: $1.93 – $7.86
One year: +54.59%

Overview

Symbol: RLMD
Sector: Health Care
Exchange: US
Currency: USD

Financials

What the filings say

Net profit, year on year: −31% (quarter to jun 2026 against jun 2025).

In $ million. Oldest period first.

Line item	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Operating profit	-23	-19	-18	-10	-10	-20	-19	-15
Other income	1	0	1	0	0	0	0	2
Net profit	-22	-19	-18	-10	-10	-20	-19	-13
EPS ($ per share)	-0.72	—	-0.58	-0.30	-0.30	—	-0.22	-0.11

Source: Inve data · income statement, quarterly · to Jun 2026

In $ million. Oldest period first.

Line item	Jun 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Equity capital	0	0	0	0	0	0	0	0
Reserves	-112	-120	-179	-305	-462	-561	-641	-698
Total liabilities	3	1	13	15	12	12	10	7
Fixed assets	0	0	0	—	—	—	—	—
Investments	—	80	115	167	143	92	41	90
Total assets	10	117	118	223	153	98	46	94

Source: Inve data · balance sheet · to Dec 2025

In $ million. Oldest period first.

Line item	Jun 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from operations	-10	-12	-28	-92	-104	-52	-52	-46
Cash from investing	—	-80	-34	-54	20	50	52	-48
Cash from financing	17	126	28	188	45	-0	-0	94
Capital expenditure	—	-85	-182	—	—	—	—	—
Free cash flow	—	-97	-210	—	—	—	—	—

Source: Inve data · cash flow · to Dec 2025

Insider filings

10 filings between Nov 5, 2025 and Sep 10, 2026.

Open market

decisions to buy or sell

Purchases

$4.03M

10 purchases by 4 insiders

Sales

None

No insider sold shares.

Who traded

open market only

Insider	Bought	Sold	Last filing
Shenouda Maged	$1.99M	—	Sep 10, 2026
TRAVERSA SERGIO	$1.54M	—	Sep 10, 2026
Ence Chuck	$299.2K	—	Nov 5, 2025
Kelly Paul Edward	$198.0K	—	Nov 5, 2025

Latest filings (30)

Date	Insider	What	Shares	Value
Sep 10, 2026	TRAVERSA SERGIO Chief Executive Officer	Purchase	100,000	$410.0K
Sep 10, 2026	Shenouda Maged Chief Financial Officer	Purchase	79,800	$339.1K
Sep 9, 2026	TRAVERSA SERGIO Chief Executive Officer	Purchase	100,000	$418.0K
Sep 9, 2026	Shenouda Maged Chief Financial Officer	Purchase	120,200	$504.8K
Dec 15, 2025	Shenouda Maged Chief Financial Officer	Purchase	11,665	$48.1K
Dec 15, 2025	TRAVERSA SERGIO Chief Executive Officer	Purchase	27,500	$113.3K
Nov 5, 2025	Kelly Paul Edward Chief Operating Officer	Purchase	90,000	$198.0K
Nov 5, 2025	Shenouda Maged Chief Financial Officer	Purchase	500,000	$1.10M
Nov 5, 2025	TRAVERSA SERGIO Chief Executive Officer	Purchase	272,500	$599.5K
Nov 5, 2025	Ence Chuck CAO and COO	Purchase	136,000	$299.2K
Aug 28, 2025	TRAVERSA SERGIO Chief Executive Officer	Purchase	55,976	$41.4K
Aug 27, 2025	TRAVERSA SERGIO Chief Executive Officer	Purchase	129,455	$86.7K
Aug 26, 2025	TRAVERSA SERGIO Chief Executive Officer	Purchase	80,545	$49.9K
May 20, 2025	TRAVERSA SERGIO Chief Executive Officer	Purchase	147,686	$82.2K
May 20, 2025	Shenouda Maged Chief Financial Officer	Purchase	60,000	$31.4K
May 19, 2025	TRAVERSA SERGIO Chief Executive Officer	Purchase	30,000	$15.0K
May 19, 2025	Shenouda Maged Chief Financial Officer	Purchase	90,000	$43.7K
May 16, 2025	Shenouda Maged Chief Financial Officer	Purchase	50,000	$22.1K
May 16, 2025	Kelly Paul Edward Chief Operating Officer	Purchase	200,000	$86.1K
May 16, 2025	TRAVERSA SERGIO Chief Executive Officer	Purchase	172,314	$77.5K
May 16, 2025	Ence Chuck CA and CO	Purchase	228,961	$103.3K
Oct 22, 2024	CASAMENTO CHARLES J Director	Gift	13,000	$0
Sep 11, 2024	TRAVERSA SERGIO Chief Executive Officer	Purchase	51,407	$153.7K
Sep 11, 2024	Shenouda Maged Chief Financial Officer	Purchase	24,120	$71.2K
Sep 10, 2024	Shenouda Maged Chief Financial Officer	Purchase	21,118	$57.7K
Sep 10, 2024	TRAVERSA SERGIO Chief Executive Officer	Purchase	33,014	$90.8K
Sep 9, 2024	Kelly Paul Edward Director	Purchase	25,000	$64.8K
Sep 9, 2024	CASAMENTO CHARLES J Director	Purchase	13,000	$33.3K
Sep 9, 2024	TRAVERSA SERGIO Chief Executive Officer	Purchase	55,579	$150.6K
Sep 9, 2024	Shenouda Maged Chief Financial Officer	Purchase	8,194	$20.9K

Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.

Your own record

Start an Inve Case for RELMADA THERAPEUTICS, INC.

Free account. Everything above stays public.

Write why you follow RELMADA THERAPEUTICS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

Create your Inve Case What an account adds

Keep reading